SAN DIEGO, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, is ...
A new research paper was published in Oncotarget, Volume 16, on March 21, 2025, titled "NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma." Researchers Andrea ...
Serum free light chain (sFLC) tests have advanced the prediction, diagnosis, and monitoring of plasma cell disorders. This webinar features two leading experts who will compare the performance of sFLC ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. I think, really, personalized medicine is ...
A few months back, good news hit the multiple myeloma community: the U.S. Food & Drug Administration voted to accept a new endpoint — MRD, or measurable residual disease — for accelerated approval of ...
Osaka, Japan – Vaccine effectiveness relies on creating a strong antibody response that can be reactivated to fight future infections. Now, researchers from Japan report that antibody-producing cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback